Valgen Medtech, as a leading innovative enterprise in the field of valve intervention in China, deeply participated with the DragonFly™ system, making an impressive appearance in a variety of forms including "surgical demonstrations + cutting-edge advancements + thematic discussions + training workshops + innovation exhibition areas." Continuously driven by original Chinese innovation, it propels atrioventricular valve intervention technology into a new era of higher-quality development, painting a future landscape together with global valve professionals.

⭕️Click on the image to jump to the original text

During the global live surgery broadcast week of the conference, Valgen Medtech presented standardized solutions for the diagnosis and treatment of complex atrioventricular valve lesions through nine complex TEER surgery demonstrations, covering various types of severe mitral and tricuspid regurgitation. This provided global clinicians with a replicable, standardized operational approach for handling challenging cases, promoting the development of TEER therapy towards refinement and standardization.

In the field of atrioventricular valve treatment, mitral valve treatment has fully entered the minimally invasive era, while tricuspid valve treatment still faces many clinical challenges. There is an urgent demand among a large number of patients with tricuspid regurgitation for safe and effective treatment options. During the conference, the Second Affiliated Hospital of Zhejiang University School of MedicineProfessor Xianbao LiuValgen Medtech Announces 12-Month Follow-Up Data from the FIM (First-in-Human) Feasibility Study of the DragonFly-T® Transcatheter Tricuspid Valve Edge-to-Edge Repair System, a China-Manufactured Innovative Device.

⭕️Click on the image to jump to the original text

The results preliminarily demonstrate its stability and feasibility in treating complex tricuspid valve lesions, further enriching the clinical evidence for domestically produced devices in this field. This achievement lays a solid foundation for subsequent larger-scale confirmatory clinical studies.

To promote the standardized and refined development of TEER technology, a special seminar titled "TEER China Tour・Master's Intensive Research Symposium" has been organized. Top experts from home and abroad have been invited to gather and conduct in-depth discussions on four key topics: the comparison of devices between China and the West, the advantages of domestically produced original research, borderline lesion treatment, and emergency TEER. The event aims to decode technical challenges, jointly explore clinical pathways, and inject Chinese wisdom into the global development of TEER.

The guests, based on their own clinical practices and research results, presented unique insights into the pain points and difficulties in technology application. Their academic viewpoints collided fiercely, inspiration kept bursting out, and the strong academic atmosphere of mutual learning allowed the attendees to fully absorb cutting-edge wisdom and broaden their diagnostic and therapeutic perspectives.

At the beginning of the meeting, University of British ColumbiaProfessor Scott LIMIn collaboration with University Hospital BonnProfessor Georg NICKENIGRespectivelyDelivered a speech, combining the global development trends of TEER technology with the current state of clinical practice in China, conveying high hopes for technological innovation and international collaboration.

Professor Scott LIMIn the speech, it was noted that TEER technology, as a significant breakthrough in interventional treatment for structural heart disease, has become one of the core methods for treating mitral regurgitation. The development speed of TEER in China has been remarkable, achieving in just a few years the leap from technology introduction to independent research and development. The rise of domestically produced devices has broken international monopolies, providing a new path for global technological advancement.

Professor Georg NICKENIGHighly Affirming China's Rapid Development and Outstanding Achievements in the TEER Field. The advancement of TEER technology relies on expert collaboration across regions and disciplines. Both China and the West have respective strengths in device design, clinical pathways, and case management. Only by enhancing exchanges and mutual learning can we drive continuous iteration and upgrading of the technology.

Subsequently,Professor Scott LIMDelivered a lecture titled "Similarities and Differences in the Application of TEER Devices Between China and the West and Clinical Implications," using the development history of TEER technology as an entry point. Compared the design features and clinical adaptation logic of mainstream TEER devices in China and the West, and combined with the pathophysiological classification of mitral valve disease, provided a clear interpretation of the selection rationale and application differences of various devices. He emphasized that the current TEER for mitral valve has entered an era of diversified device toolboxes, where clinical application requires a deep understanding of technical characteristics and disease pathology. It is essential to adhere to a pathology-oriented approach and rely on anatomical evidence to achieve precise matching between devices and lesions, ultimately enhancing the safety and effectiveness of surgeries.

The First Affiliated Hospital of Sun Yat-sen UniversityProfessor Xiaodong Zhuang"Individualized Application of China-Produced Original TEER Devices in Commissural Lesions"

Beijing Anzhen Hospital, Capital Medical UniversityProfessor Haibo ZhangAnalysis of "Application Techniques of DragonFly™ in Emergency TEER", dissecting core challenges such as complex reflux mechanisms and limited operating space in emergency procedures. He pointed out that the multi-model design, free-angle locking, and independent capture advantages of DragonFly™ perfectly meet the high demands of emergency surgeries for instruments. Referring to real cases, he emphasized the importance of meticulous preoperative assessment and standardized operation, confirming its stable performance under extreme conditions like papillary muscle rupture, assisting surgeons to rescue patients calmly and saving lives for critically ill patients.

Taipei Veterans General HospitalProfessor Song SixianShare "Clinical Advantages of China-Produced Original TEER Devices》，Combined with Three Classic Cases: A Comparison of Differences Between International Mainstream Devices and DragonFly™, Emphasizing the Unique Performance of DragonFly™’s Free-Angle Locking and Elastic Occlusion Net. This feature effectively balances residual regurgitation and transvalvular pressure gradients while considering immediate tension and long-term stability, overcomes preoperative sizing limitations, and fully demonstrates the prominent advantages and adaptability of China-developed devices in clinical applications.

Yunnan Fuwai Cardiovascular HospitalProfessor Zhu Da、Professor Li JinJoint teaching, centered on "thematic lectures + practical exercises," covering the full-process training of TEER for mitral and tricuspid valves.Prof. Zhu Da, Prof. Li JinLecture on intraoperative strategies and techniques for complex mitral valve cases, with detailed ultrasound explanations and hands-on practice using anatomical models, complemented by synchronized hands-on training with a visual simulator; the tricuspid valve session focuses on foundational knowledge, covering basics, indications, and key points of preoperative assessment, paired with simulator and ultrasound model practice. The entire training balances advanced and introductory content, offering substantial insights to enhance participants' practical TEER skills and imaging guidance capabilities, promoting the standardized dissemination of the technology.